5.3. Analysis.
Comparison 5: Gemcitabine versus one‐third dose Bacillus Calmette‐Guérin (BCG), Outcome 3: Grade III–V adverse events
Comparison 5: Gemcitabine versus one‐third dose Bacillus Calmette‐Guérin (BCG), Outcome 3: Grade III–V adverse events